G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)

NEXT STORY
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
PREV STORY
Global Vial Adaptors for Reconstitution Drug Markets, 2020-2027 with Short-term Impact of COVID-19 for 2020-2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Biochip Markets, 2016-2020 & 2021-2026: Drug Discovery & Development, Disease Diagnostics, Genomics, Others

author_avatar
NASDAQ Market News

RELYPSA ANNOUNCES FDA APPROVAL OF VELTASSA(TM) (PATIROMER) FOR ORAL SUSPENSION FOR THE TREATMENT OF HYPERKALEMIA

First new medicine for the treatment of hyperkalemia, or high blood potassium levels, in ...

author_avatar
NASDAQ Market News

Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

ALPHARETTA, Ga., June 13, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical ...

author_avatar
NASDAQ Market News